Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by State Street Corp

State Street Corp decreased its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 39.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,192,436 shares of the biotechnology company’s stock after selling 2,088,430 shares during the quarter. State Street Corp owned about 2.10% of Heron Therapeutics worth $6,353,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Marshall Wace LLP boosted its position in shares of Heron Therapeutics by 256.2% during the 2nd quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after purchasing an additional 1,266,697 shares in the last quarter. Clearline Capital LP boosted its holdings in Heron Therapeutics by 48.9% during the third quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after buying an additional 731,246 shares in the last quarter. AQR Capital Management LLC grew its position in Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock worth $2,125,000 after buying an additional 568,238 shares during the last quarter. Congress Park Capital LLC grew its position in Heron Therapeutics by 25.3% in the third quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after buying an additional 399,577 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Heron Therapeutics by 369.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock valued at $1,273,000 after acquiring an additional 286,160 shares during the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

Shares of HRTX opened at $1.55 on Friday. The business’s 50 day simple moving average is $1.53 and its 200-day simple moving average is $2.14. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The company has a market capitalization of $235.75 million, a P/E ratio of -8.61 and a beta of 1.67.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.03). The firm had revenue of $32.81 million for the quarter, compared to the consensus estimate of $36.40 million. During the same quarter in the previous year, the firm earned ($0.17) EPS. On average, sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HRTX has been the topic of several recent analyst reports. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 19th. Needham & Company LLC restated a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.